Subclinical Liver Disease Is Associated with Subclinical Atherosclerosis in Psoriasis: Results from Two Observational Studies.
Autor: | Gonzalez-Cantero A; Department of Dermatology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain., Teklu M; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Sorokin AV; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Prussick R; The Department of Dermatology, The George Washington School of Medicine & Health Sciences, Washington, District of Columbia, USA., González-Cantero J; Department of Radiology, Gregorio Marañon Hospital, Madrid, Spain., Martin-Rodriguez JL; Department of Radiology, University Hospital San Cecilio, Granada, Spain., Patel N; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Parel PM; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Manyak GA; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Teague HL; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Rodante JA; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Keel A; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Pérez-Hortet C; Department of Dermatology, Complejo Hospitalario de Toledo, Toledo, Spain., Sanchéz-Moya AI; Department of Dermatology, Complejo Hospitalario de Toledo, Toledo, Spain., Jiménez N; Department of Dermatology, Hospital Universitario Ramon y Cajal, Madrid, Spain., Ballester A; Department of Dermatology, Hospital Universitario Ramon y Cajal, Madrid, Spain., Solis J; Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain., Fernandez-Friera L; Centro Integral de Enfermedades Cardiovasculares HM CIEC, HM Hospitales, Madrid, Spain., Barderas MG; Department of Vascular Physiopathology, Hospital Nacional de Parapléjicos, SESCAM, Toledo, Spain., Gonzalez-Calvin JL; Department of Gastroenterology, University Hospital San Cecilio, Granada, Spain., Jaen P; Department of Dermatology, Hospital Universitario Ramon y Cajal, Madrid, Spain., Playford MP; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Dey AK; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Gelfand JM; Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Mehta NN; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: nehal.mehta@nih.gov. |
---|---|
Jazyk: | angličtina |
Zdroj: | The Journal of investigative dermatology [J Invest Dermatol] 2022 Jan; Vol. 142 (1), pp. 88-96. Date of Electronic Publication: 2021 Jul 19. |
DOI: | 10.1016/j.jid.2021.05.034 |
Abstrakt: | Psoriasis is associated with a higher risk of liver diseases. We investigated the impact of hepatic steatosis (European cohort) and hepatic inflammation (United States cohort) on subclinical atherosclerosis. In the European cohort (n = 76 psoriasis participants and 76 controls), nonalcoholic fatty liver disease, assessed by the sonographic hepatorenal index, was more prevalent in psoriasis than in controls (61% vs. 45%; P = 0.04). Participants with psoriasis with nonalcoholic fatty liver disease had a higher prevalence of subclinical atherosclerosis (ultrasonographic presence of plaque in femoral or carotid arteries) than participants with psoriasis without nonalcoholic fatty liver disease (61% vs. 23%; P = 0.006) and controls with nonalcoholic fatty liver disease (61% vs. 32%; P < 0.05). Sonographic hepatorenal index was a determinant of subclinical atherosclerosis in psoriasis (OR = 3.5; P = 0.01). In the United States cohort (n = 162 participants with psoriasis who underwent positron emission tomography and coronary computed tomography angiography), those with high hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake had higher noncalcified (1.3 [0.49 mm 2 ] vs. 1.0 [0.40 mm 2 ]), fibrofatty (0.23 [0.15 mm 2 ] vs. 0.11 [0.087 mm 2 ]), and lipid-rich necrotic core (4.3 [2.3 mm 2 ] vs. 3.0 [1.7 mm 2 ]) coronary burden (all P < 0.001). Hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake associated with noncalcified (β = 0.28; P < 0.001), fibrofatty (β = 0.49; P < 0.001), and lipid-rich necrotic core (β = 0.28; P = 0.003) burden. These results show the downstream cardiovascular effects of subclinical liver disease in psoriasis. (Published by Elsevier Inc.) |
Databáze: | MEDLINE |
Externí odkaz: |